Journal
CANCER
Volume 120, Issue 7, Pages 1002-1009Publisher
WILEY
DOI: 10.1002/cncr.28522
Keywords
imatinib; dasatinib; BCR-ABL mutations; resistance; acute lymphoblastic leukemia
Categories
Funding
- European LeukemiaNet
- AIL
- AIRC
- PRIN [prot. 2009JSMKY]
- Fondazione CARISBO
Ask authors/readers for more resources
BACKGROUNDPatients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib with acquisition of BCR-ABL kinase domain (KD) mutations. To analyze the changes that second-generation tyrosine kinase inhibitors (TKIs) have brought in mutation frequency and type, a database review was undertaken of the results of all the BCR-ABL KD mutation analyses performed in the authors' laboratory from January 2004 to January 2013. METHODSInterrogation of the database retrieved 450 mutation analyses in 272 patients with Ph+ ALL. Prescreening of samples was performed with denaturing high-performance liquid chromatography (D-HPLC), followed by direct sequencing of D-HPLC-positive cases. RESULTSBCR-ABL KD mutations were detected in 70% of imatinib-resistant patients, with T315I, E255K, and Y253H mutations accounting for 75% of cases. Seventy-eight percent of the patients reported to be resistant to second-generation TKIs after imatinib failure were positive for mutations, and 58% of them had multiple mutations. Analysis of patients relapsing on dasatinib revealed a newly acquired T315I mutation in almost two-thirds of the cases. Direct sequencing detected no mutations at diagnosis, even in patients who relapsed after a few months. CONCLUSIONSSecond-generation TKIs ensure a more rapid debulking of the leukemic clone and have much fewer insensitive mutations, but long-term disease control remains a problem, and the T315I mutation is revealed to be an even more frequent enemy. BCR-ABL KD mutation screening of patients with Ph+ ALL who are receiving imatinib or second-generation TKIs would be a precious ally for timely treatment optimization. In contrast, the clinical usefulness of conventional direct sequencing at diagnosis seems to be very low. Cancer 2014;120:1002-1009. (c) 2013 American Cancer Society. Second-generation tyrosine kinase inhibitors ensure a more rapid debulking of the leukemic clone and have much fewer insensitive mutations than imatinib. However, long-term disease control of Philadelphia chromosome-positive acute lymphoblastic leukemias remains a problem, and the T315I mutation has become more frequent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available